Is Option B+ the best choice

The Lancet

Volumn 381, Issue 9863, 2013, Pages 269-271

  Coutsoudis, Anna ^a   Goga, Ameena ^b   Desmond, Chris ^c   Barron, Peter ^d   Black, Vivian ^c   Coovadia, Hoosen ^e  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; DECISION MAKING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NOTE; PATIENT ADVOCACY; PREGNANT WOMAN; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 84872973996     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61807-8     Document Type: Note

References (14)

1. World Health Organization HIV/AIDS Programme. Use of antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. Executive Summary. April, 2012. http://www.who.int/hiv/PMTCT-update.pdf (accessed Oct 8, 2012).
2. UNICEF. A business case for Options B and B+ to eliminate mother to child transmission of HIV by 2015. July, 2012. http://eptctasiapacifi c.org/content/business-case-options-b-and-b-eliminate-mother-childtransmission- hiv-2015-model-methodology (accessed Oct 3, 2012).
3. AIDS 2012. Washington DC. July, 2012. http://aids2012.org/WebContent/ File/AIDS2012-Plenary-Media-Release-25-July-2012-EN.pdf (accessed Oct 8, 2012).
4. Shapiro R, Hughes M, Oguwa A. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362: 2282-94.
5. The Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11: 171-80.
6. Hargrove J, Humphrey J, for the ZVITAMBO Study Group. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 2010; 24: 11-14.
7. Cohen M, Chen Y, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
8. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206: 1695-705.
9. Struik GM, den Exter RA, Munthali C, et al. The prevalence of renal impairment among adults with early HIV disease in Blantyre, Malawi. Int J STD AIDS 2011; 22: 457-62.
10. Siberry G, Williams P, Mendez H, et al, for the Pediatric HIV/AIDS Cohort Study (PHACS). Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26: 1151-59.
11. Rosen S, Fox M, Gill C. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4: 1691-701.
12. Unge C, Södergård B, Marrone G. Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: a prospective cohort study. PLoS Med 2010; 5: 1-12.
13. Nachega J, Uthman O, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-, middle-and high-income countries: a systematic review and meta-analysis. AIDS 2012; 26: 2039-52.
14. Wagner B, Blower S. Universal access to HIV treatment versus universal "test and treat": transmission, drug resistance & treatment costs. PLoS One 2012; 7: e41212.